Skip to content

R&D at other companies

Autodesk logo
AutodeskADSK
$421M+6.9%
Samsara logo
SamsaraIOT
$97.57M+17.2%
Wabtec logo
WabtecWAB
$56M+21.7%
Uber Technologies logo
Uber TechnologiesUBER
$951M+16.7%

Other financials

Income statement

See full
Revenue$939.9M+11.8%
Gross profit$646.3M+15.2%
Operating income$144.0M+47.7%
Net income$98.9M+48.3%
EPS (diluted)$0.42+55.6%

Balance sheet

See full
Cash & equivalents$234.1M-19.3%
Total debt$1.4B+2.3%
Total equity$5.6B+4.0%
Total assets$9.0B+1.0%

Cash flow

See full
Operating cash flow$274.7M+76.5%
CapEx$6.1M-7.6%
Free cash flow$268.6M+80.3%

Valuation

See full
Market cap$11.46B+6.2%
Enterprise value$12.65B+6.3%
P/E25.1×+18.0×
P/S3.1×+0.1×

Profitability

See full
Gross margin69.5%+3.3pp
Operating margin17.3%+4.7pp
Net margin12.4%-30.0pp
FCF margin11.8%-3.4pp

Returns & leverage

See full
Return on equity8.3%-22.7pp
Debt / equity0.3×0.0×
Current ratio+0.2×

Where this comes from

Reported directly by Trimble Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Trimble Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Trimble Inc.'s r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Trimble Inc.'s R&D?
Trimble Inc. (TRMB) reported R&D of $169.5M in Q1 2026.
How has Trimble Inc.'s R&D changed year-over-year?
Trimble Inc.'s R&D increased by 6.9% year-over-year, from $158.5M to $169.5M.
What is the long-term trend for Trimble Inc.'s R&D?
Over 4 years (2021 to 2025), Trimble Inc.'s R&D has grown at a 4.1% compound annual growth rate (CAGR), from $536.6M to $630.7M.
What does R&D mean?
Spending dedicated to creating new products or improving existing technology.
How do you interpret R&D?
Consistent investment signals a commitment to innovation, while sharp cuts may indicate short-term focus or financial distress.
How does R&D compare across companies?
Standard operating expense line item for technology and pharmaceutical companies; often compared as a percentage of revenue.